NCT04918511View on ClinicalTrials.gov

A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 27, 2021

Primary Completion Date

March 31, 2024

Study Completion Date

December 31, 2025

Conditions
Relapse Multiple MyelomaMultiple Myeloma
Interventions
DRUG

OPD5

OPD5 solution for i.v. infusion

Trial Locations (3)

62500

University Hospital Brno, Clinic of Internal Medicine - Hematology and Oncology, Brno

Unknown

University Hospital Ostrava, Clinic of Hematooncology, Ostrava

Charles University and General Hospital in Prague, 1st Department of Medicine - Department of Hematology, First Faculty of Medicine, Prague

Sponsors

Lead Sponsor

Oncopeptides AB
All Listed Sponsors
lead

Oncopeptides AB

INDUSTRY

NCT04918511 - A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter